Krakow, Poland – June 2, 2021 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, is pleased to invite everyone interested to participate in a live webinar: “Synthetic lethality in cancer treatment.”
The webinar will feature lectures on the synthetic lethality approach in cancer research. With the help of leading researchers in the field, we will discuss the concept of synthetic lethality (SL) in discovery and development of anti-cancer therapies. We will present how Ryvu is exploiting synthetic lethality approach, with its dedicated discovery engine, focusing currently on WRN and MTAP projects. In addition, we will take a look at the perspectives and the competitive landscape in the SL space.
Date: Wednesday, June 9, 2021
Time: 3:00 pm CEST (15:00)
Detailed agenda:
I. Introduction
Speaker: Krzysztof Brzozka, PhD, Chief Scientific Officer, Ryvu Therapeutics
II. Synthetic Lethality in Research and Development of Anti-cancer Therapies
Speaker: Michal Mikula, PhD, Maria Sklodowska-Curie National Research Institute of Oncology
III. Ryvu Therapeutics – Synthetic Lethal Discovery Engine and Pipeline Overview
Speaker: Mateusz Nowak, PhD, Director of Early Discovery and Innovation, Ryvu Therapeutics
IV. Synthetic Lethality: Perspectives on the Competitive Landscape, Partnerships and Investments
Speaker: Vatnak Vat-Ho, Chief Business Officer, Ryvu Therapeutics
V. Q&A session
To sign up, visit: https://event.webinarjam.com/register/152/l91qwaqz
Synthetic Lethality
One of the challenges in the development of new oncology therapeutics is the limited number of protein targets known to be addressable with small molecules. Synthetic lethality allows the identification of novel protein targets and mechanisms of cancer cell sensitivity that can be used therapeutically.
Compounds active on specific synthetic lethal targets selectively kill tumor cells of a precisely defined molecular pattern, characterized by a specific genetic, epigenetic or metabolic characteristic. This is the approach actively investigated at Ryvu that allows the generation of compounds with highly specific and well-characterized activity.